Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
Status:
Unknown status
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Velcade (bortezomib), thalidomide and dexamethasone (VTD) has been demonstrated to be a
highly effective combination in both patients with previously untreated and those with
relapsed multiple myeloma. In previously untreated patients VTD demonstrated clear
superiority to TD as induction therapy prior to planned tandem autologous stem cell
transplant.
The rationale of this trial is to combine a 'gold standard' antiMM combination with the HDAC
inhibitor Panobinostat. There is emerging data to support the concept of clinical synergy
between BTZ and HDACi's.
The purpose of this study is to determine the maximum tolerated dose (MTD) and estimated
response rates of panobinostat, administered in combination with VTD, in subjects with
relapsed and relapsed/refractory multiple myeloma.